ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lucoridalines

Also written as “DA-9701”, “DA-9701-R” and “Motilitone 30mg”.

Its studies are mostly in Dyspepsia, led by 2 companies.

Drug pageDA-9701: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 19, 20134 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dong-A STits history only31 open or runningphase 4since Mar 19, 2013Mar 19, 2013Oct 2027phase 4 · NCT07686679
Dong-A Pharmaceutical10 open or runningphase 4since Oct 26, 2012Oct 26, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dong-A Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2012First study: phase 4 study in Healthy Female and MaleFirst studyNCT01719575 · 30 enrolled · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Dong-A Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01719575Healthy Female and Male · Korea, Republic of4CompletedNov 201230

How it is read

Names in the registry

  • “DA-9701”, 1 entry
  • “DA-9701-R”, 1 entry
  • “Motilitone 30mg”, 1 entry
  • “Motilitone ®”, 1 entry
  • “Motilitone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.